BIOMAT Database Logo BIOMAT Database Logo

[Monitoring of plasma diphenylhydantoin levels in epileptic patients]. 1983

C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Distribution of plasma phenobarbital, diphenylhydantoin and primidone levels in epileptic patients.
January 1977, Folia psychiatrica et neurologica japonica,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
[Plasma diphenylhydantoin concentration in epileptic patients].
September 1974, Harefuah,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Proceedings: Monitoring of plasma levels in epileptic patients.
January 1976, Arzneimittel-Forschung,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Monitoring drug noncompliance in epileptic patients: assessing phenobarbital plasma levels.
January 1985, Therapeutic drug monitoring,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
[Plasma levels of diphenylhydantoin (DPH) and phenobarbitone (PB) in epileptic patients resistant to drug treatment (author's transl)].
January 1977, Rivista di patologia nervosa e mentale,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Editorial: Plasma diphenylhydantoin levels.
October 1974, Australian and New Zealand journal of medicine,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Plasma levels of diphenylhydantoin and the control of adult epileptic seizures: a Chilean experience.
October 1980, Epilepsia,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Elevated serum alkaline phosphatase levels in the epileptic patients treated with diphenylhydantoin.
January 1970, Folia psychiatrica et neurologica japonica,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
[Clinical significance of blood levels of diphenylhydantoin orally administered to epileptic patients].
June 1985, Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry,
C M Lezama-Dávila, and G Olmos-García de Alba, and A López-Anaya, and F Valarezo-Crespo
Plasma level monitoring of oxcarbazepine in epileptic patients.
January 2000, Archives of medical research,
Copied contents to your clipboard!